| Title: | Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib |
| Authors: | Asahina, Hajime Browse this author →KAKEN DB |
| Oizumi, Satoshi Browse this author →KAKEN DB |
| Inoue, Akira Browse this author |
| Kinoshita, Ichiro Browse this author →KAKEN DB |
| Ishida, Takashi Browse this author |
| Fujita, Yuka Browse this author |
| Sukoh, Noriaki Browse this author |
| Harada, Masao Browse this author |
| Maemondo, Makoto Browse this author |
| Saijo, Yasuo Browse this author |
| Dosaka-Akita, Hirotoshi Browse this author →KAKEN DB |
| Isobe, Hiroshi Browse this author →KAKEN DB |
| Nukiwa, Toshihiro Browse this author |
| Nishimura, Masaharu Browse this author →KAKEN DB |
| Keywords: | Epidermal growth factor receptor (EGFR) |
| Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) |
| Gefitinib |
| Non-small cell lung cancer (NSCLC) |
| Chemotherapy |
| readministration |
| Issue Date: | Apr-2011 |
| Publisher: | Karger |
| Journal Title: | Oncology : International Journal for Cancer Research and Treatment |
| Volume: | 79 |
| Issue: | 5-6 |
| Start Page: | 423 |
| End Page: | 429 |
| Publisher DOI: | 10.1159/000326488 |
| PMID: | 21474967 |
| Abstract: | Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. Methods: Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung cancer (NSCLC) who had achieved objective response to initial gefitinib and subsequently received cytotoxic chemotherapy after disease progression with initial gefitinib. The primary endpoint was the objective response rate with gefitinib readministration. Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), quality of life ((QOL), and toxicity. Changes in lung cancer-related symptoms were evaluated using the seven-item lung cancer subscale of the questionnaire. Results: Sixteen patients were enrolled between February 2005 and January 2008. Most had received ≥ 3 regimens of chemotherapy. Response and disease-control rates for all patients were 0% and 44%. Median PFS and OS were 2.5 months and 14.7 months, respectively. Four of 7 patients with stable disease experienced a long duration (≥ 6 months) of disease control without severe toxicity. Symptom improvement was observed in 2 of 12 patients (17%) for whom QOL was evaluable. Conclusion: Gefitinib represents a useful therapeutic option for selected previous gefitinib responders. |
| Rights: | Copyright © 2011 S. Karger AG, Basel |
| Type: | article (author version) |
| URI: | http://hdl.handle.net/2115/45486 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
